Phoenix Asia Swings to Loss, Gross Margin Collapses to 4.6%
PHOE has more than doubled off its 52-week low of $6.56.
Summary
Phoenix Asia swung to a $1.2M loss in FY2026 as gross margin collapsed to 4.6%. The filing also discloses a pending $1B pharma acquisition and a $20M convertible note to its controlling shareholder.
Key Events · Earnings and Guidance · PHOE
-
Net Loss of $1.2M
Phoenix Asia reported a net loss of $1,200,960 for FY2026, compared to net income of $1,026,318 in FY2025.
-
Gross Margin Collapse
Gross profit margin fell from 29.5% to 4.6%, driven by a 41.5% increase in subcontracting costs.
-
Material Weaknesses Persist
Management concluded internal controls over financial reporting remain ineffective as of March 31, 2026, citing four material weaknesses.
-
$1B Pharma Acquisition
Subsequent to year-end, the company agreed to acquire ACEA Pharma for 100 million newly issued shares valued at $1.0 billion.
Analysis · PHOE · Real Estate & Construction
Phoenix Asia reported a net loss of $1.2 million for fiscal 2026, a sharp reversal from a $1.0 million profit the prior year. The deterioration was driven by a collapse in gross margin from 29.5% to 4.6%, as subcontracting costs surged 41.5% while revenue slipped 2.2%. The company also disclosed that its internal controls over financial reporting remain ineffective, with four material weaknesses identified. Additionally, the filing reveals two major subsequent events: a $1 billion all-stock acquisition of a clinical-stage pharma company and a $20 million convertible note issued to its controlling shareholder. These developments fundamentally alter the company's risk profile and strategic direction.
At the time of this filing, PHOE was trading at $22.30 on NASDAQ in the Real Estate & Construction sector, with a market capitalization of approximately $481.7M. The 52-week trading range was $6.56 to $133.12. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.